ReviewEndocrinology and metabolism (Seoul, Korea)2020
Encountering COVID-19 as Endocrinologists.
Review in Endocrinology and metabolism (Seoul, Korea), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Unraveling the Mystery: COVID-19 and Diabetic Complications - A Journey from Pathophysiology to Treatment.Current diabetes reviews · 2026Review
- Determining the frequency of thyroid involvement in chest CT scans of COVID-19 patients and its correlation with the severity of lung involvement and survival of patients in 2020.Frontiers in endocrinology · 2024Article
- Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional StudyJournal of clinical research in pediatric endocrinology · 2023Article
- Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study.Journal of clinical medicine · 2023Article
- New-onset and relapsed Graves' disease following COVID-19 vaccination: a comprehensive review of reported cases.European journal of medical research · 2023Review
- COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel.International journal of molecular sciences · 2022Review
- Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects.Journal of endocrinological investigation · 2021Review
- COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.Diabetes & metabolism journal · 2021Article
- SARS-CoV-2 (COVID-19) and the Endocrine System.Journal of the Endocrine Society · 2020Review
- Collateral Damage of the COVID-19 Pandemic on Nutritional Quality and Physical Activity: Perspective from South Korea.Obesity (Silver Spring, Md.) · 2020Article
- Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study.Diabetes & metabolism journal · 2020Article
- Managing Diabetes During the COVID-19 Pandemic.European endocrinology · 2020Article
- AFES A.S.-O.N.E.: ASEAN Survey Of Needs in Endocrinology in the Time of the COVID-19 Pandemic.Journal of the ASEAN Federation of Endocrine Societies · 2020Article
- WhatsApp-Based virtual consultation in clinical practice during COVID times: A prospective institutional study.Annals of African medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.